FOR US HEALTHCARE PROFESSIONALS ONLY
INVEGA SUSTENNA® was evaluated in a 24-month international† study vs a group of 6 common oral antipsychotics1
Over 7 months’ difference in time to relapse
compared to a group of oral antipsychotics
Oral antipsychotics received by patients:
aripiprazole, haloperidol, olanzapine, paliperidone ER, quetiapine, risperidone
Primary endpoint: Significantly longer time to relapse in patients receiving INVEGA SUSTENNA® vs oral antipsychotics (P=0.019; HR=1.5, 95% CI=1.1-2.2)1‡
Secondary endpoint: Significantly fewer patients relapsed in the INVEGA SUSTENNA® vs oral antipsychotics arm§ (14.8% and 20.9%, respectively; P=0.032)1
Relapse criteria1
Relapse was defined as any of the following:
CGI=Clinical Global Impressions scale; CI=confidence interval; ER=extended release; HR=hazard ratio; PANSS=Positive and Negative Syndrome Scale.
*All patients diagnosed 1 to 5 years previously with ≥2 relapses requiring hospitalization.1
†The study was conducted in 26 countries, excluding the United States.1
‡Relapse defined by any of the following: psychiatric hospitalization; increase in the level of psychiatric care and an increase of 25% from baseline in PANSS total score (or an increase of 10 points if baseline score ≤40); deliberate self-injury; suicidal or homicidal ideation; violent behavior resulting in injury to another person or property damage; substantial clinical deterioration; required dose of antipsychotic exceeds the maximum approved dose.1
§At 24 months, 52 (14.8%) patients on INVEGA SUSTENNA® experienced a relapse vs 76 (20.9%) in the oral antipsychotic group.1
Recently diagnosed study design1
A 24-month, international study comparing INVEGA SUSTENNA® with 6 common oral antipsychotics in adult patients with recently diagnosed schizophrenia
Key inclusion criteria
Key exclusion criteria
Study medications
2-week acute oral treatment phase
Patients randomized (1:1) to INVEGA SUSTENNA® or oral treatment arms entered a 2-week initial acute oral treatment phase
24-month core treatment phase
CGI=Clinical Global Impressions scale; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; ER=extended-release; LAI=long-acting injectable; PANSS=Positive and Negative Syndrome Scale; QD=every day.
*The study was conducted in 26 countries, excluding the United States.
References: 1. Schreiner A, Aadamsoo K, Altamura AC, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169(1-3):393-399. 2. Data on file. Janssen Pharmaceuticals, Inc.
Back to Top